

Table S2. Adaptive Radiotherapy Risk Profile

Adaptive strategy – Risk Profile			
	Low risk	Intermediate risk	High risk
Tumor localization	NCC/MS//HPC	NPC/OPC/L	NPC/OPC/OCC/L
Loose mask		Loose mask detected in weeks 3-4	Loose mask detected during week 1
BMI/B-body	If initial weight <100 kg	If initial weight <100 kg	Initial weight >100 kg
CHRT		no chemoradiation	chemoradiation
Postoperative RT		No	Yes
Stage	T1/N0	T2-T3 / <N1	T3-T4 / N1-N3
Parotid Glands		parotid glands also move to the body midline during radiation therapy	parotid glands also move to the body midline during radiation therapy
		difference between the planning scan and the CBCT/MVCT are greater than 3mm on 3-4 consecutive scans at any point of the external contour	difference between the planning scan and the CBCT/MVCT are greater than 3mm on 3-4 consecutive scans at any point of the external contour
Nodal Status		Dominant pretreatment nodal in region II-IV	Dominant pretreatment nodal in region II-IV
			CTV moves outside the body during treatment
			CTV covering more than 10% of initial PG volume
PTV			PTV outside the Body during treatment >3mm on 3-4 consecutive scans
Suggested control Replan-CT	Observation	2-5th week of treatment	3-5th week of treatment

Abbreviations: H&N, head and neck; PG, parotid gland; CTV, clinical target volume; PTV, planning target volume; BMI, body mass index; CHRT, chemoradiotherapy; OPC, oropharyngeal cancer; OCC, oral cavity cancers; and Other (NPC, nasopharynx, L=larynx, HPC=hypopharynx, CUP=cancer of unknown primary, NCC=nasal cavity cancer, MS=maxillary sinus cancer).